Centers | ||
Therapeutic Accelerator Program (TAP) | UCSC Chemical Screening Center | BLAVATNIK CENTER for Drug Discovery |
Test |
We are a shared research facility dedicated to improving human health by finding therapeutic agents against a wide variety of diseases, dedicated to advancing scientific knowledge and technologies, and dedicated to education of the next generation of... |
The BLAVATNIK CENTER for Drug Discovery (BCDD) is a fully integrated center for translational research, based at Tel Aviv University, that comprises medicinal chemistry, biological target identification and computer-assisted drug design units under... Read more |
Partnerships |
Events |
Jobs |
Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all Bayer and UCSF Enter into a 10year Research & Development PartnershipBayer and University of California, San Francisco (UCSF) have signed a 10year master research and development agreement. The agreement provides a broad template for collaboration between the two groups around common areas of research interest... View all Astra Zeneca and University of Pennsylvania Partner to Develop Treatments to Manage ObesityAstra Zeneca has entered into a research collaboration agreement with University of Pennsylvania's Institute for Diabetes, Obesity and Metabolism to develop small and or large molecules to manage obesity, control glucose and lipid metabolism in... View all |
No EVENTS for listing |
No Job Posts |


